111 Inc (YI) - Total Liabilities
Based on the latest financial reports, 111 Inc (YI) has total liabilities worth $1.99 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
111 Inc - Total Liabilities Trend (2016–2025)
This chart illustrates how 111 Inc's total liabilities have evolved over time, based on quarterly financial data. See YI working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
111 Inc Competitors by Total Liabilities
The table below lists competitors of 111 Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Resverlogix Corp.
TO:RVX
|
Canada | CA$98.31 Million |
|
ESS Tech Inc
NYSE:GWH
|
USA | $39.13 Million |
|
Wing Yip Food Holdings Group Limited American Depositary Shares
NASDAQ:WYHG
|
USA | $40.97 Million |
|
Murano Global Investments PLC Ordinary Shares
NASDAQ:MRNO
|
USA | $15.88 Billion |
|
TherapeuticsMD Inc
NASDAQ:TXMD
|
USA | $10.78 Million |
|
Andromeda Metals Ltd
AU:ADN
|
Australia | AU$2.27 Million |
|
GWR Group Ltd
AU:GWR
|
Australia | AU$7.38 Million |
|
Blue Star Helium Ltd
AU:BNL
|
Australia | AU$32.72 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down 111 Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 111 Inc (YI) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.83 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.90 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 111 Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 111 Inc (2016–2025)
The table below shows the annual total liabilities of 111 Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.99 Billion | -17.45% |
| 2024-12-31 | $2.41 Billion | -14.43% |
| 2023-12-31 | $2.81 Billion | -0.45% |
| 2022-12-31 | $2.83 Billion | +23.00% |
| 2021-12-31 | $2.30 Billion | +35.46% |
| 2020-12-31 | $1.70 Billion | +102.76% |
| 2019-12-31 | $836.37 Million | +159.22% |
| 2018-12-31 | $322.65 Million | -27.42% |
| 2017-12-31 | $444.56 Million | +21.44% |
| 2016-12-31 | $366.08 Million | -- |
About 111 Inc
111, Inc., together with its subsidiaries, operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates through two segments, B2C and B2B. The company offers supply chain integration services that help pharmaceutical companies manage products through online and offline channels; product promotion, customer analytics, patient education,… Read more